폐 마커 시장 보고서 : 암 유형별, 마커 유형별, 최종사용자별, 지역별(2025-2033년)

The global lung marker market size reached USD 482.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,104.6 Million by 2033, exhibiting a growth rate (CAGR) of 9.6% during 2025-2033.

Generally, four major types of lung markers, including EGFR, EML4-ALK, KRAS, and BRAF, are used during lung intervention procedures or lung surgeries and diagnosis. Furthermore, the markers are used to detect, diagnose, predict, and monitor the tumor, based on which the treatment is prescribed to the patient. Lung markers are only used as an additional tool to identify cancer along with several imaging tests and biopsy. Owing to this, lung markers are extensively used in thoracoscopic surgeries across hospitals, ambulatory surgical clinics, and specialty clinics, among several other healthcare facilities.

The rising demand for lung markers can be attributed to the high prevalence of respiratory disorders, such as pleural effusion, pleural mesothelioma, pleural plaque, etc., due to the increasing air pollution levels, across the globe. Besides this, the high exposure to passive smoking, along with a family history of lung cancer further drives the number of patients suffering from lung cancer, thereby augmenting the demand for lung markers. Additionally, the surging geriatric population, along with the hectic consumer lifestyles leading to a high smoking rate, further accelerate the risks of several respiratory disorders. Apart from this, the increasing healthcare expenditures by various governments for early diagnosis and pre-treatment of life-threatening diseases, such as lung cancer, are also propelling the rising utilization of lung markers at a global level. Furthermore, rising investments in several research and development activities in the field of lung cancer diagnostics and treatment is further catalyzing the demand for lung markers. In addition to this, the increasing usage of lung markers in hospitals, surgery centers, clinics, and their various applications in therapeutic purposes has also catalyzed the product demand.

Key Market Segmentation:

Breakup by Cancer Type:

• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

Breakup by Marker Type:

• EGFR
• EML4-ALK
• KRAS
• BRAF
• Others

Breakup by End User:

• Hospitals
• Diagnostic Labs
• Others

Breakup by Region:

• North America
• United States
• Canada
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Chile
• Peru
• Others
• Middle East and Africa
• Turkey
• Iran
• Others

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Beckman Coulter, Inc., Fujirebio Europe N.V., Hologic, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers, and BioSpace, Inc.

Key Questions Answered in This Report:

• How has the global lung marker market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global lung marker market?
• What are the key regional markets?
• What is the breakup of the market based on the cancer type?
• What is the breakup of the market based on the marker type?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global lung marker market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Lung Marker Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact Of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Cancer Type

• 6.1 Non-Small Cell Lung Cancer (NSCLC)
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Small Cell Lung Cancer (SCLC)
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Marker Type

• 7.1 EGFR
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 EML4-ALK
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 KRAS
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 BRAF
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Diagnostic Labs
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Europe
  • 9.2.1 Germany
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 France
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 United Kingdom
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 Italy
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Spain
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Russia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Asia Pacific
  • 9.3.1 China
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 Japan
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 India
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 South Korea
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Australia
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Indonesia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Argentina
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
  • 9.4.4 Colombia
    • 9.4.4.1 Market Trends
    • 9.4.4.2 Market Forecast
  • 9.4.5 Chile
    • 9.4.5.1 Market Trends
    • 9.4.5.2 Market Forecast
  • 9.4.6 Peru
    • 9.4.6.1 Market Trends
    • 9.4.6.2 Market Forecast
  • 9.4.7 Others
    • 9.4.7.1 Market Trends
    • 9.4.7.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Turkey
    • 9.5.1.1 Market Trends
    • 9.5.1.2 Market Forecast
  • 9.5.2 Iran
    • 9.5.2.1 Market Trends
    • 9.5.2.2 Market Forecast
  • 9.5.3 Others
    • 9.5.3.1 Market Trends
    • 9.5.3.2 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Indicators

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Thermo Fisher Scientific Inc
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Agilent Technologies, Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Beckman Coulter, Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Fujirebio Europe N.V.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Hologic, Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 F. Hoffmann-La Roche Ltd
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Siemens Healthineers
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 BioSpace, Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis